Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, 100 and 200 mg) vs Placebo in Patients with Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Netupitant (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Helsinn
- 23 Jun 2012 Additional location (Germany) added as reported by European Clinical Trials Database.
- 05 Aug 2011 New trial record